心血管肿瘤学临床中的高血压。

Hypertension in the Cardio-Oncology Clinic.

机构信息

Department of Internal Medicine, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, 3rd Floor, Columbus, OH 43210-1267, USA.

Cardiovascular Division, John T. Milliken Department of Internal Medicine, Cardio-Oncology Center of Excellence, Washington University School of Medicine in St. Louis, 660 South Euclid Avenue, Campus Box 8086, St Louis, MO 63110, USA.

出版信息

Heart Fail Clin. 2019 Oct;15(4):487-495. doi: 10.1016/j.hfc.2019.06.010.

DOI:10.1016/j.hfc.2019.06.010

PMID:31472884

Abstract

As cancer therapies improve, the population of survivors of cancer has increased, and the long-term effects of cancer treatments have become more apparent. Cardiotoxicity is a well-established adverse effect of many antineoplastic agents. Hypertension is common in survivors of cancer, can be caused or worsened by certain agents, and has been shown to increase the risk of other cardiovascular diseases including heart failure. Pretreatment risk assessment and careful monitoring of blood pressure during therapy is essential. Aggressive management of preexisting or incident hypertension in survivors of cancer is paramount to decrease the risk of heart failure and other cardiovascular diseases in these patients.

摘要

随着癌症治疗方法的改进，癌症幸存者的人数有所增加，癌症治疗的长期影响也变得更加明显。心脏毒性是许多抗肿瘤药物的一种公认的不良反应。高血压在癌症幸存者中很常见，可以由某些药物引起或加重，并且已经表明它会增加其他心血管疾病（包括心力衰竭）的风险。在治疗前进行风险评估和仔细监测血压至关重要。积极治疗癌症幸存者的现有或新发高血压至关重要，可降低这些患者心力衰竭和其他心血管疾病的风险。